Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more
Qiagen N.V. (NYSE:QGEN; Xetra:QIA) said Thierry Bernard will become the permanent CEO after serving on an interim basis since October. Bernard, who joined Qiagen in 2015 as SVP of the molecular diagnostics business area, takes the helm as the biotech ramps up RNA extraction kit production to provide diagnostic testing during the COVID-19 pandemic. Thermo Fisher Scientific Inc. (NYSE:TMO) is acquiring Qiagen for $11.5 billion (see “FDA Expanding U.S. COVID-19 Test Capacity”).
CytomX Therapeutics Inc. (NASDAQ:CTMX), which partnered with Astellas Pharma Inc. (Tokyo:4503) this week to develop bispecifics for immuno-oncology, hired Carlos Campoy as SVP and CFO. He was CFO of Alder BioPharmaceuticals Inc., which H. Lundbeck A/S (CSE:LUN) acquired in October (see “Astellas Becomes CytomX’s First New Partner Since 2017”). ...